Equities analysts expect that Arcadia Biosciences Inc (NASDAQ:RKDA) will announce earnings of ($0.65) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Arcadia Biosciences’ earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.61). Arcadia Biosciences reported earnings per share of ($0.14) in the same quarter last year, which indicates a negative year-over-year growth rate of 364.3%. The business is scheduled to announce its next earnings report on Wednesday, March 25th.
According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($3.74) per share for the current year, with EPS estimates ranging from ($4.33) to ($3.15). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.54) to ($1.66). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.27). The business had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.
In other Arcadia Biosciences news, Director Kevin Comcowich acquired 5,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $5.88 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at $117,600. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders bought 32,200 shares of company stock valued at $188,076. Company insiders own 3.30% of the company’s stock.
Large investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in Arcadia Biosciences during the second quarter valued at about $32,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Arcadia Biosciences during the second quarter valued at about $34,000. Squarepoint Ops LLC purchased a new stake in Arcadia Biosciences during the third quarter valued at about $124,000. Sabby Management LLC grew its position in Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock valued at $234,000 after acquiring an additional 30,000 shares during the period. Finally, Vanguard Group Inc. grew its position in Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock valued at $359,000 after acquiring an additional 37,472 shares during the period. 8.03% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:RKDA traded up $0.21 during midday trading on Wednesday, reaching $5.42. The company’s stock had a trading volume of 172,571 shares, compared to its average volume of 1,262,908. The firm has a market cap of $45.15 million, a price-to-earnings ratio of -1.01 and a beta of -2.98. The company has a quick ratio of 5.27, a current ratio of 5.58 and a debt-to-equity ratio of 0.11. Arcadia Biosciences has a 1 year low of $1.82 and a 1 year high of $10.40. The business has a 50 day moving average price of $4.76 and a 200 day moving average price of $4.68.
About Arcadia Biosciences
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Read More: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.